A RESPONSE TO "THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER".
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33251994.
- Also identified by DOI 10.18553/jmcp.2020.26.12.1616 and PMC identifier 10391022.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<b>DISCLOSURES:</b> The writing of this letter was sponsored by Roche/Genentech. All authors are employees of, and hold stocks in, F. Hoffmann-La Roche Ltd/Genentech Inc.
Medical subject headings
- Lung Neoplasms
- Protein Kinase Inhibitors